Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

2021374 citationsJournal Article

Authors

Good health and well-being

Published in: The Lancet

Volume 397, Issue 10292, pp. 2361-2371

Field-Weighted Citation Impact: 41.08